Immunology · CorticosteroidRegulatory Approvalregulatorymid-term

FDA Approves Deflazacort Supplement Application by Upsher Smith Labs

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Sandoz24 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/6/2026, 6:00:40 PM

Assessment confidence: 55% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of the Deflazacort supplement by Upsher Smith Labs is significant as it strengthens their competitive position in the corticosteroid market. This could lead to shifts in market dynamics, necessitating strategic responses from other players in the immunology space. Regulatory context from FDA (FDA AP — DEFLAZACORT (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and consider strategies to counteract Upsher Smith's strengthened position. The strongest clinical anchor is Study of Smith-Lemli-Opitz Syndrome (ClinicalTrials.gov), moderate corpus alignment. In Immunology · Corticosteroid, 8 regulatory and 2 competitive items passed relevance filtering for Upsher Smith Labs.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient (Merck) — sponsor/company relevance (merck). Secondary pressure from FDA Approves Supplement for Levetiracetam by Chartwell RX.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DEFLAZACORT (SUPPL) (FDA). Entity match (upsher smith labs). Relevant agencies in corpus: FDA, PMDA. The approval indicates a successful regulatory pathway for Upsher Smith, which may set a precedent for future applications in the corticosteroid category.

Key Risks

Elevated medium regulatory exposure for Upsher Smith Labs could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval may allow Upsher Smith to capture additional market share, potentially affecting revenue streams for competitors with similar corticosteroid products.
Portfolio teams should assess the implications of this approval on market share and consider strategies to counteract Upsher Smith's strengthened position.

What Would Change This Assessment

This becomes more urgent if Monitor for market launch details and any competitive responses from other corticosteroid manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DEFLAZACORT (SUPPL)
FDAhigh relevance
Entity match (upsher smith labs)
FDA document
View source
FDA AP — DEFLAZACORT (SUPPL)
FDAhigh relevance
Entity match (upsher smith labs)
Raw openFDA evidence
View raw openFDA evidence
FDA AP — DEFLAZACORT (ORIG)
FDAhigh relevance
Entity match (deflazacort)
FDA document
View source
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
[IBENTO][IBENTO]PMDA-ATC GMP Inspection Seminar 2026 applications open
PMDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LOSARTAN POTASSIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Study of Smith-Lemli-Opitz Syndrome
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
AIM-IBD: A Phase 2b Trial of Microbiome-Targeted Investigational Product in Ulcerative Colitis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Exploring the Feasibility of Transcranial Ultrasound Stimulation in the Treatment of Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Approves Supplement for Levetiracetam by Chartwell RX
Humanexa Signalsmedium relevance
Moderate corpus alignment

Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Upsher Smith Labs
Deflazacort
corticosteroid market
competitors in immunology

Commercial impact

medium

The approval may allow Upsher Smith to capture additional market share, potentially affecting revenue streams for competitors with similar corticosteroid products.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Upsher Smith, which may set a precedent for future applications in the corticosteroid category.

What to watch

Monitor for market launch details and any competitive responses from other corticosteroid manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.